News | December 14, 2024
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
The trademark rights for these brands will be transferred to Lupin by March next year.
The trademark rights for these brands will be transferred to Lupin by March next year.
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Aims to achieve CDMO sales of US$ 400 million by 2028
Subscribe To Our Newsletter & Stay Updated
